43
LIFESCIENCELEADER.COM NOVEMBER 2014
the adaptive immune system but also the
innate system.
E s s e n t i a l c o m p o n e n t s ?
[SEETO] Everything is driven by the
science, and we need to conduct more
for us is not just immunostimulators and
checkpoint inhibitors, not just the gas
on and brakes off. We are looking at the
tumor microenvironment and promoting
the enhancement of tumor antigen pre-
sentation, so we are focused not only on
data has also indicated that biomarkers
and genetic signatures may be used to
identify the patient population that will
best respond to treatment, but validation
of the biomarkers for selection has yet to
be confirmed in the clinic.
G e n e ra l c o m m e n t ?
We highly value our preclinical data as a
driver for clinical programs. We believe
that well-conducted studies may help
with the rational design of combination
therapies and can assist in the appropriate
design of clinical trials. Having said that,
demonstrating a mechanism of action for
the therapy in patients early on is criti-
cal to justify further development. This
will allow for more efficient, effective, and
innovative clinical trial designs that will
translate into effective cancer therapies.
M E D I M M U N E /A S T R A Z E N E C A
Numerous immunotherapies in
development, including MEDI4736
(PD-L1) now in Phase 3, tremelim-
umab (CTLA-4, licensed from Pfizer),
MEDI6469 (OX40, from AgonOx),
and MEDI0680 (PD-1, acquired
through Amplimmune).
BAHIJA JALLAL, PH.D.
Executive Vice President,
AstraZeneca,
Head of MedImmune
EDWARD BRADLEY, M.D.
Senior Vice President, R&D;
Oncology, iMED Head
REG SEETO, M.D.
Vice President, Head of
Partnering and Strategy
W h y c o m b i n a t i o n s ?
[BRADLEY] We believe in combinations
and have a robust clinical portfolio with
CTLA-4, PD-1, PD-L1, and OX40 in devel-
opment both as monotherapy and in com-
binations. The next wave of combinations